JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells.
Eschweiler S, Wang A, Ramírez-Suástegui C, von Witzleben A, Li Y, Chee SJ, Simon H, Mondal M, Ellis M, Thomas GJ, Chandra V, Ottensmeier CH, Vijayanand P.
Eschweiler S, et al. Among authors: chandra v.
Cell Rep. 2023 Feb 28;42(2):112040. doi: 10.1016/j.celrep.2023.112040. Epub 2023 Jan 25.
Cell Rep. 2023.
PMID: 36701231
Free PMC article.